BETA: Please send your feedback!
REGENXBIO
NAS:RGNX
Biotechnology
$1.67bn
SMALL cap
$46.50
(1.80%)
7.3159%
since start of 2019
—
- —
- —
- —
- —
- —
- —
- —
- —
- —
- —
- —
- 1
-
CF
-
PP
-
WC
-
DP
-
CH
-
ES
-
WS
-
CG
-
EP
-
CM
-
FL
-
GD
- —
- 1
- 2
- 3
- 4
- 5
About
Biotechnology
Founded 2008
REGENXBIO, Inc. is a biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. The company was founded by Kennth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.
website
Headquarters
Executives
Name | Title | Gender |
Patrick J. Christmas | Senior Vice President & General Counsel | Male |
Donald J. Hayden, Jr., MBA | Chairman | Male |
Kenneth T. Mills | President, Chief Executive Officer & Director | Male |
Vit Vasista, MBA | CFO & Principal Accounting Officer | Male |
Olivier Danos, PhD | Chief Scientific Officer | Male |
Stephen Yoo, MD | Chief Medical Officer | Male |
Kimberly Sloan | Senior Vice President-Human Resources | Female |
Lynne Fahey McGrath, PhD | Vice President-Regulatory Affairs | Female |
James M. Wilson, MD, PhD | Founder | null |
Rickey Reinhardt, MD, PhD | Vice President-Clinical Research & Development | null |
Jerome W. Jackson, MBA | Vice President-Information Technology | Male |
Mindful Investing Summary
- —
- 1
- 2
- 3
- 4
- 5
-
Carbon Footprint — N/A
-
Pollution Prevention — N/A
-
Water Conservation — N/A
-
Data & Privacy Protection — N/A
-
Consumer Health, Wellness & Safety — N/A
-
Employee Ownership, Satisfaction, Benefits & Pay — N/A
-
Workplace Health and Safety — N/A
-
Integrity of Corporate Governance — N/A
-
Ethical Practices — N/A
-
Usage of Conflict Materials — N/A
-
Forced Labor — N/A
-
Diversity of Corporate Leadership 1
REGENXBIO - Competitors and Related Companies
How REGENXBIO stacks up to its peers in the Biotechnology industry or with competing business segments.
REGENXBIO
NAS:RGNX
Biotechnology
$1.67bn
SMALL cap
$46.50
(1.80%)
7.3159%
since start of 2019
—
Loading…